4.4 Article

Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139

Journal

MSPHERE
Volume 6, Issue 4, Pages -

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/mSphere.00114-21

Keywords

Vibrio cholerae O139; O-specific polysaccharide; synthetic saccharides; conjugate vaccine; immune response; immunity

Categories

Funding

  1. National Institutes of Health
  2. National Institute of Allergy and Infectious Diseases [AI106878, AI099243, AI137164]
  3. Fogarty International Center, Training Grant in Vaccine Development and Public Health [TW005572]
  4. Emerging Global Fellowship Award [TW010362]
  5. Intramural Research Program of the NIH
  6. Grant Agency of Slovak Academy of Sciences VEGA [2/0093/17]
  7. Bill and Melinda Gates Foundation [OPP1148213]
  8. NIDDK
  9. Bill and Melinda Gates Foundation [OPP1148213] Funding Source: Bill and Melinda Gates Foundation

Ask authors/readers for more resources

The study found that immune responses to O139 OSP are not prominent following vaccination with the currently available oral cholera vaccine in immunologically naive individuals, suggesting that vaccines targeting V. cholerae O139 should be based on native OSP-core or terminal tetrasaccharide.
Cholera caused by Vibrio cholerae O139 could reemerge, and proactive development of an effective O139 vaccine would be prudent. To define immunoreactive and potentially immunogenic carbohydrate targets of Vibrio cholerae O139, we assessed immunoreactivities of various O-specific polysaccharide (OSP) related saccharides with plasma from humans hospitalized with cholera caused by O139, comparing responses to those induced in recipients of a commercial oral whole-cell killed bivalent (O1 and O139) cholera vaccine (WC-O1/O139). We also assessed conjugate vaccines containing selected subsets of these saccharides for their ability to induce protective immunity using a mouse model of cholera. We found that patients with wild-type O139 cholera develop IgM, IgA, and IgG immune responses against O139 OSP and many of its fragments, but we were able to detect only a moderate IgM response to purified O139 OSP-core, and none to its fragments, in immunologically naive recipients of WC-O1/O139. We found that immunoreactivity of O139-specific polysaccharides with antibodies elicited by wild-type infection markedly increase when saccharides contain colitose and phosphate residues, that a synthetic terminal tetrasaccharide fragment of OSP is more immunoreactive and protectively immunogenic than complete OSP, that native OSP-core is a better protective immunogen than the synthetic OSP lacking core, and that functional vibriocidal activity of antibodies predicts in vivo protection in our model but depends on capsule thickness. Our results suggest that O139 OSP-specific responses are not prominent following vaccination with a currently available oral cholera vaccine in immunologically naive humans and that vaccines targeting V. cholerae O139 should be based on native OSP-core or terminal tetrasaccharide. IMPORTANCE Cholera is a severe dehydrating illness of humans caused by Vibrio cholerae serogroup O1 or O139. Protection against cholera is serogroup specific, and serogroup specificity is defined by O-specific polysaccharide (OSP). Little is known about immunity to O139 OSP. In this study, we used synthetic fragments of the O139 OSP to define immune responses to OSP in humans recovering from cholera caused by V. cholerae O139, compared these responses to those induced by the available O139 vaccine, and evaluated O139 fragments in next-generation conjugate vaccines. We found that the terminal tetrasaccharide of O139 is a primary immune target but that the currently available bivalent cholera vaccine poorly induces an anti-O139 OSP response in immunologically naive individuals.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available